Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches
Open Access
- 28 April 2025
- journal article
- review article
- Published by Springer Nature in Mammalian Genome
- Vol. 36 (2) , 444-464
Abstract
Olfactory dysfunction (OD) is considered one of the early signs of Parkinson’s disease (PD), affecting over 90% of PD patients. OD often appears several years before the onset of motor symptoms and is therefore considered an early biomarker of PD. Recent studies have shown that COVID-19 infection might lead to worsening of symptoms and acceleration of disease progression in neurodegenerative disorders, where OD is a common symptom to both. Hence, it is essential to accurately monitor olfactory fitness in clinical settings using any of the currently available olfactory function tests. Even after a quarter of a century of the discovery of α-synuclein (α-syn) pathogenesis in PD, many aspects related to the α-syn pathogenesis in OD remain unknown. Currently, there is no definitive cure for PD; the disease management options include dopaminergic medications, deep brain stimulations, stem cells, and immunotherapy. Generating reliable PD animal models is critical for understanding the molecular pathways and neural circuits affected by disease conditions. This might contribute to the development and validation of new therapeutic approaches. This review discusses the known mechanisms of α-syn aggregated forms causing neuronal death, the recent developments in the PD preclinical models with ODs, and the treatment strategies employed.Keywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology, India (BT/RLF/Re‐entry/45/2014)
- University Grants Commission
- Wellcome Trust DBT India Alliance (IA/S/22/2/506517)
This publication has 243 references indexed in Scilit:
- Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson DiseaseJAMA Neurology, 2022
- Clinical Diagnosis and Current Management Strategies for Olfactory DysfunctionJAMA Otolaryngology–Head & Neck Surgery, 2019
- Noninvasive delivery of an α‐synuclein gene silencing vector with magnetic resonance–guided focused ultrasoundMovement Disorders, 2018
- Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta‐analysisInternational Forum of Allergy & Rhinology, 2015
- G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndromeAnnals of Neurology, 2013
- Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's diseaseMovement Disorders, 2013
- Neuron‐to‐neuron transmission of α‐synuclein fibrils through axonal transportAnnals of Neurology, 2012
- Effects of olfactory training in patients with olfactory lossThe Laryngoscope, 2009
- The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementiaAnnals of Neurology, 2003
- Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification TestArchives of Neurology, 2003